Effect of Revaccination with Recombinant Hepatitis B Virus Vaccine Containing Higher Antigen Concentration in Non-responder Children

Riska Habriel Ruslie1*, Gontar Alamsyah Siregar2

1Department of Child Health, Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia; 2Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Abstract

BACKGROUND: Hepatitis B is a global health problem carrying significant morbidity and mortality. Vaccination against hepatitis B virus (HBV) has been implemented with good effectiveness, but a small proportion of children do not respond well after complete routine vaccination. They are called non-responders and are at higher risk for HBV infection.

AIM: The objective of the study was to determine the effect of revaccination with recombinant HBV vaccine containing higher antigen concentration in non-responder children.

METHODS: A prospective study was conducted from January 2018 until December 2019. Inclusion criteria were children aged 9–15 months and had three doses of recombinant HBV at 0, 1, and 6 months old. Exclusion criteria were the presence of acute or chronic hepatitis B and conditions which alter immune function and immunosuppressant medications consumption. Demographic and clinical characteristics were gathered from each subject along with serum HBsAb titer examination. Subjects with serum anti-hepatitis B surface antigen (HBsAb) titer of <10 IU/L were classified into non-responders and underwent revaccination with 3 doses of vaccine containing 20 µg HBsAg. The revaccination series was repeated until all subjects showed seroconversion. After each series, repeated serum HBsAb titer measurements were conducted.

RESULTS: A total of 400 children were enrolled in this study with a mean age of 12.1 (SD 2.64) months. Subjects were dominated with females (54.0) and normal nutritional status (79.0). The rate of non-responsiveness was 9.0%. Of all non-responders, 88.9% experienced seroconversion after the first revaccination series. After the third revaccination series, all subjects had serum HBsAb titer at the protective level.

CONCLUSION: Revaccination with recombinant HBV vaccine containing higher antigen concentration in non-responder children is effective.

Introduction

Hepatitis B still becomes a global health problem [1], [2]. Approximately 700 million adults have a history of prior hepatitis B and 120 million individuals are chronic hepatitis B surface antigen (HBsAg) carriers [3]. It is estimated that 500,000 until 1.2 million global deaths are related to hepatitis B. The prevalence of hepatitis B is higher in Asia compared to Europe [1]. Most developed countries have low hepatitis B endemicity and the transmission usually occurs horizontally from high-risk behaviors such as homosexual and drug user, blood transfusion, hemodialysis, and healthcare workers [2]. Vaccination is a preventive measure against hepatitis B virus infection and its complications [4], [5]. Vaccination against hepatitis B has been invented for a few decades ago. Universal childhood vaccination program involving this vaccine has greatly reduced the rate of both acute and chronic hepatitis B virus (HBV) infections [3], [6].

In the Netherlands, the vaccine should be administered at 0, 1, and 2 months [6]. In Indonesia, routine vaccination against hepatitis B utilizes a vaccine with a dose of 10 µg. Each person should receive a total of 3 doses at 0, 1, and 6 months [7]. Protective response following vaccination is marked by anti-hepatitis B surface antigen (HBsAb) titer of 10 IU/L or higher [1], [6]. If someone has reached protective HBsAb level, he/she will have a lower risk of hepatitis B for at least 10 years [5]. It is reported that 5–30% person does not have a protective response after routine vaccination. They are known as non-responders [3], [4], [6], [8] while those who had HBsAb titer between 10 and 100 IU/L are called low responders [3], [4], [8]. Another literature defines non-responder as a subject who is unable to produce protective HBsAb titer despite receiving 2 series of HBV vaccination after acute or chronic hepatitis B have been excluded and low responder as a non-responder who experiences serocconversion after the second series of HBV vaccination [7]. Non-responders are at
high risk of HBV infection and its complications. They also become sources of hepatitis B spreading [6].

Repeated vaccination or revaccination is recommended for non-responders to overcome the risks [6], [7], [9]. There are several methods in conducting revaccination including giving additional dose at varying times, repeating standard schedule, administering a double dose, giving vaccine with higher antigen content, and administering vaccine through the intradermal route [5]. Our study aimed to determine the effect of revaccination with HBV vaccine containing higher antigen concentration in non-responder children.

Methods

This prospective study was conducted in Universitas Sumatera Utara Hospital and several private clinics in Medan, Indonesia from January 2018 until December 2019. Subjects were children aged 9–15 months previously vaccinated with three doses of recombinant HBV vaccine according to the governmental program at 0, 1, and 6 months old. Exclusion criteria were children suffering from acute or chronic hepatitis B, consuming immunosuppressant medications, and having conditions which alter immune function such as acquired immune deficiency syndrome. Subjects were obtained using a total sampling method. Demographic and clinical characteristics were gathered from each subject. Determination of serum HBsAb titer was conducted using HBsAb commercial kit (Diapro, Italy) according to the manufacturer’s instruction. A venous blood sample was drawn and centrifugated to obtain the serum. Sera were kept at a temperature of −20°C until the procedure was performed. Subjects with serum HBsAb titer of <10 IU/L were classified into non-responders and further underwent revaccination with 3 doses of Engerix-B (GlaxoSmithKline) containing 20 µg HBsAg at the following 0, 1, and 6 months. The revaccination series was repeated until all subjects showed seroconversion into the protective level. After each series, repeated serum HBsAb titer measurements were conducted. Data analysis was done with statistical software and the results will be presented in tables. This study was approved by the Health Research Ethical Committee, Medical School, Universitas Sumatera Utara.

Results

A total of 400 children fulfilled the inclusion criteria of this study. Mean age of subjects was 12.1 (SD 2.64) months. Gender distribution was almost similar with slight female domination. A total of 79% subject had a normal nutritional status. The amount of non-responders in this study was 36 (9%) children (Table 1). The 36 children followed revaccination program, as mentioned above.

Table 1: Baseline characteristics of subjects

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, months (SD)</td>
<td>12.1 (2.64)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>184 (46.0)</td>
</tr>
<tr>
<td>Female</td>
<td>216 (54.0)</td>
</tr>
<tr>
<td>Nutritional status, n (%)</td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>48 (12.0)</td>
</tr>
<tr>
<td>Normal</td>
<td>316 (79)</td>
</tr>
<tr>
<td>Overweight</td>
<td>36 (9)</td>
</tr>
<tr>
<td>Immune response, n (%)</td>
<td></td>
</tr>
<tr>
<td>Non-responder</td>
<td>36 (9.0)</td>
</tr>
<tr>
<td>Protective level</td>
<td>364 (91.0)</td>
</tr>
</tbody>
</table>

Of 36 non-responder children who underwent the first series of revaccination, 32 children achieved protective serum HBsAb titer. The rest 4 children followed the second series of revaccination. In the end of the series, serum HBsAb titer of all subjects was in protective level (Table 2).

Table 2: Immune response of subjects after the first and second series of revaccination

<table>
<thead>
<tr>
<th>Immune response</th>
<th>After the first series of revaccination</th>
<th>After the second series of revaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protective level</td>
<td>4 (11.1)</td>
<td>32 (88.9)</td>
</tr>
<tr>
<td>Protective level</td>
<td>0 (0.0)</td>
<td>4 (100.0)</td>
</tr>
</tbody>
</table>

Discussion

Hepatitis B is a disease caused by hepatitis B virus infection which may progress to chronic disease and cause severe complications such as liver cirrhosis and hepatocellular carcinoma [2], [10], [11]. Vaccine against HBV was introduced in the early 1980s and WHO urged all countries to involve the vaccine into their immunization programs [1], [8], [11]. All HBV vaccines contain HBsAg, a protein from hepatitis B virus envelope. Hepatitis B surface antigen is expected to activate lymphocyte cells through antigen-presenting cells and preserve immunity in a longer period. There are 2 types of HBV vaccine: Plasma-derived vaccine and recombinant vaccine. Adjuvants are added to improve the immunogenicity of the vaccine [8]. Complete schedule of vaccination against HBV (3 or 4 doses according to regional protocol) gives safe and effective protection. However, a particular subject does not produce protective HBsAb even after complete vaccination [10]. A study from Iran involving children and adolescents aged 6–18 years reported that the response to HBV vaccine was only 38.5% [1]. Data from Bangladesh reported that 88.67% vaccinated individuals had protective HBsAb titer [2]. About 4% vaccinated newborns with HBV vaccine does not reach protective antibody level [1], [12] where 0.4% does not respond even after revaccination while the rest 3.6%
achieves protective antibody titer [12]. The result in our study was similar to the literature above. As many as 91% children receiving routine hepatitis B vaccination reached protective serum HBsAb titer. The rate of non-responder in our study was 9.0%.

Poor response toward vaccination is associated with male gender, advanced age, obesity, smoking, genetic predisposition, type of vaccine, number of injection, subcutaneous administration of vaccine, adjuvant used, and vaccine handling [2], [4], [6], [7], [9]. Low ratio of T helper cell compared to T cytotoxic cell, high ratio of natural killer T killer cell, and psychosocial stress shortly after vaccination is other risk factors for unsatisfied respond toward vaccination [10]. Older age is associated with suboptimal response toward HBV vaccine due to waning of immunity [1], [8]. Subcutaneous injection may decrease antigen-presenting cell's activation and inhibit antigen presentation to lymphocytes [7]. Obesity is associated with decreased number and function of lymphocytes [9]. Higher body weight also hampers immune response from decreased vaccine absorption in adipose tissue [1]. A case report described that obese women who had received six doses of HBV vaccine failed to achieve protective HBsAb titer until she underwent gastropasty Roux-en-Y gastric bypass to overcome her obesity. She needed 3 additional doses after the surgery to experience seroconversion [9]. Genetic susceptibility in HBV vaccine non-responsiveness is associated with HLA haplotypes such as DRB1*13, DRB1*17, DRB1*14, DQB1*0604, DAOA*0102, and DRB1*1302 [8], [11]. The role HLA-C4A locus in the responsiveness toward HBV vaccination is hypothesized. The presence of C4AQ0 allele is associated with non-responsiveness to HBV vaccination even in the absence of DRB1*0301, DQB1*02, or DRB1*0701. The allele is expected to impair the function of complement and further antibody response to T-dependent antigen. This condition is observed in both adults and neonates [12]. Other literatures stated that the presence of HLA-DR2, HLA-DR3, HLA-DR7, HLA-DR14, and HLA-B8 was the genetic–associated risk factor for poor vaccination response [2], [4], [10]. There was no significant gender predisposition in our study. All subjects were also aged <2 years. Most subjects had a normal nutritional status.

A study evaluated revaccination response in non-responder adults after receiving 3 doses of Engerix-B or HBVaxpro-10. They were revaccinated by either Twinrix (GlaxoSmithKline), HBVaxPro40 (Merck Sharp & Dohme), or Fendrix (GlaxoSmithKline) compared to Engerix-B (GlaxoSmithKline). Statistical analysis showed that the proportion of responders in HBVaxPro40 and Fendrix groups was higher compared to Engerix-B group as the control. HBsAb titer was also higher in both groups compared to control. This was probably caused by a higher antigen dose in Fendrix and HBVaxPro40. More potent adjuvant used in both vaccines might also contribute to higher response [6].

Clemens et al. studied a proportion of low- and non-responder adults after hepatitis B vaccination at 0, 1, and 6 months. They administered booster vaccine (Engerix-B, SmithKline Beecham Biologicals) with higher HBV antigen dose (20 µg) at 2 months interval until the subjects had HBsAb titer of ≥100 mIU/mL. After the 3rd booster, all non-responders had HBsAb titer of 100 mIU/mL or higher [10]. Han et al. conducted a study in Guangdong and found that the rate of non-responder and low responder of 3.1% and 28.9%, respectively, in infants receiving 3 doses of routine HBV vaccination. The routine HBV vaccine used contains 5 µg antigens. Revaccination was conducted using 3 doses of HBV vaccine with a higher content of antigen. All of the non-responders achieved low responder and responder status after revaccination [3]. The literature above confirmed the result of our study. We found that revaccination with HBV vaccine containing higher antigen concentration resulted in better immune response in non-responder children. However, we needed 2 series of revaccination to achieve serum HBsAb titer of ≥10 IU/L in all subjects who previously were non-responders.

In contrast with our study, Joukar et al. showed that a double dose of vaccine was more effective compared to a single dose in the early revaccination program. However, after the third dose of vaccine, both single and double dose gave similar effectiveness. All non-responsive subjects experienced seroconversion after the third dose of revaccination [5]. Their result was supported by several studies. A study in Bandung, Indonesia, showed that 5.5% of 144 children were non-responders. After receiving the second series of revaccination, all of them had protective HBsAb titer [7]. Cardell et al. administered 3 doses of combined hepatitis A and B vaccine as a revaccination program. After the third dose of vaccination, 95% non-responders produced a protective level of HBsAb [11]. Ahad et al. reported that booster HBV vaccine significantly increased HBsAb titer [2].

Intradermal administration of HBV vaccine is suggested to be more effective in particular populations, including non-responders. Intradermal administration also requires less amount of antigen to induce protective immunity and may cut the cost of immunization [4]. This statement is supported by Cardell et al. Their study found that administration of hepatitis B vaccine intradermally resulted in antibody production to a protective level in 68.3% study subjects. Administration of additional 1 booster vaccine increased the percentage to 88.9% [11]. However, the effectiveness of intradermal administration of HBV vaccine needs further study before being applied to non-responders [4].

The limitation of our study was that we could not rule out confounding factors non-responsiveness status such as genetic predisposition and vaccine handling. We also did not conduct follow-up after
revaccination series to rule out the factors that might contribute to vaccination response. However, this was the first study in our region regarding the management of HBV vaccine non-responder children. In conclusion, revaccination with recombinant HBV vaccine containing higher antigen concentration in non-responder children is effective.

References


